Nitrogen In R Patents (Class 514/619)
-
Publication number: 20140179794Abstract: The present invention concerns the use of levomilnacipran as medicinal product in functional recovery after a cerebrovascular accident or traumatic brain injury. The pharmaceutical compositions containing levomilnacipran are exclusively those not containing dextromilnacipran to a proportion of more than 5% by weight of the levomilnacipran/dextromilnacipran mixture, to avoid compromising functional recovery due to the alpha1-blocking property of dextromilnacipran.Type: ApplicationFiled: July 27, 2012Publication date: June 26, 2014Applicant: PIERRE FABRE MEDICAMENTInventor: Pierre Sokoloff
-
Publication number: 20140179700Abstract: Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, ?-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from an ERK inhibitor, a MEK inhibitor, and a Raf inhibitor. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells are also provided.Type: ApplicationFiled: April 30, 2012Publication date: June 26, 2014Applicant: Duke UniveristyInventor: Rahima Zennadi
-
Patent number: 8754131Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: January 28, 2014Date of Patent: June 17, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Publication number: 20140163111Abstract: The invention relates to compositions including porous biomolecule-containing metal-organic frameworks and methods for their preparation. The porous biomolecule-containing metal-organic frameworks can include a metal component and a biomolecule component. The pores located within the frameworks have a pore space and said pore space is capable to adsorb materials therein. These compositions of the invention are useful in a wide variety of applications, such as, but not limited to, hydrogen and carbon dioxide sequestration, separation and storage; carbon dioxide uptake; and drug storage and release.Type: ApplicationFiled: February 13, 2014Publication date: June 12, 2014Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: NATHANIEL LOUIS ROSI, JIHYUN AN
-
Publication number: 20140163041Abstract: The present invention relates to methods and compositions for the treatment or prevention of diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing diseases and disorder associated with myeloproliferative and lymphoproliferative disorders.Type: ApplicationFiled: February 8, 2012Publication date: June 12, 2014Applicant: ORYZON GENOMICS S.A.Inventors: Matthew Colin Thor Fyfe, Tamara Maes, Marc Martinell Pedemonte
-
Patent number: 8748339Abstract: The present invention relates to a composition, comprising a 5-amino-3-oxo-2,3-dihydro-pyrazole of the formula I as defined in the claims and the description and at least one active compound II selected from groups A) to I) in a synergistically effective amount.Type: GrantFiled: June 4, 2009Date of Patent: June 10, 2014Assignee: BASF SEInventors: Markus Gewehr, Jochen Dietz, Thomas Grote, Egon Haden
-
Patent number: 8748493Abstract: The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a biological sample obtained from a subject.Type: GrantFiled: March 22, 2010Date of Patent: June 10, 2014Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Karine Clement, Michele Guerre Millo, Nadia Naour
-
Publication number: 20140155332Abstract: Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.Type: ApplicationFiled: March 2, 2012Publication date: June 5, 2014Inventors: Judy Lieberman, Fabio Petrocca
-
Publication number: 20140148398Abstract: Compounds useful for the treatment of giardiasis are described.Type: ApplicationFiled: October 12, 2011Publication date: May 29, 2014Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
-
Patent number: 8735453Abstract: The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y? is a pharmaceutically acceptable anion.Type: GrantFiled: January 16, 2013Date of Patent: May 27, 2014Assignee: Silence Therapeutics GmbHInventors: Oliver Keil, Jörg Kaufmann, Ansgar Santel
-
Patent number: 8729048Abstract: This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer cells that are homologous recombination-deficient are likely to be susceptible or resistant to PARP inhibitors and platinating agents are provided.Type: GrantFiled: November 16, 2012Date of Patent: May 20, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Scott H. Kaufmann, Anand G. Patel
-
Patent number: 8729130Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.Type: GrantFiled: September 15, 2012Date of Patent: May 20, 2014Assignee: The Broad Institute, Inc.Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
-
Patent number: 8722743Abstract: The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A?), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A?) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH2C(=0)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, and —CH2CH2CH2CH2—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy.Type: GrantFiled: April 19, 2011Date of Patent: May 13, 2014Assignee: Oryzon Genomics S.A.Inventors: Alberto Ortega Munoz, Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe
-
Patent number: 8716347Abstract: Tramadol or a pharmaceutically acceptable salt thereof is used in the manufacture of a pharmaceutical preparation for the treatment of functional gastrointestinal disorders such as irritable bowel syndrome.Type: GrantFiled: May 30, 2006Date of Patent: May 6, 2014Assignee: Euro-Celtique S.A.Inventor: David Fowler
-
Patent number: 8716285Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to processes for making said compounds and uses of said compounds, in particular their use as medicaments, more particularly their use as medicaments in the treatment of cancer.Type: GrantFiled: September 7, 2011Date of Patent: May 6, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Lei Guo, Guozhi Tang, Zhanguo Wang, Jason Christopher Wong, Weixing Zhang
-
Patent number: 8691875Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.Type: GrantFiled: September 15, 2012Date of Patent: April 8, 2014Assignee: Broad Institute, Inc.Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
-
Publication number: 20140073651Abstract: The invention relates to benzamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.Type: ApplicationFiled: February 21, 2012Publication date: March 13, 2014Applicant: Actelion Pharmaceuticals Ltd.Inventors: Kurt Hilpert, Francis Hubler, Mark Murphy, Dorte Renneberg
-
Patent number: 8669290Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: November 28, 2012Date of Patent: March 11, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Patent number: 8669286Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.Type: GrantFiled: September 26, 2012Date of Patent: March 11, 2014Assignee: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Jeffrey D. Kearbey
-
Publication number: 20140066513Abstract: A method for a prevention and/or treatment of irritable bowel syndrome or amelioration of a symptom thereof in a subject, comprises administering to said subject an effective amount of a compound of formula I:Type: ApplicationFiled: August 26, 2013Publication date: March 6, 2014Applicant: MediciNova, Inc.Inventors: Kazuko MATSUDA, Yuichi Iwaki, Kale Ruby
-
Patent number: 8653129Abstract: The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.Type: GrantFiled: April 11, 2011Date of Patent: February 18, 2014Assignee: M. Alphabet 1, LLCInventors: Howard Fein, Mindy B. Berlin
-
Patent number: 8642799Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: GrantFiled: April 11, 2013Date of Patent: February 4, 2014Assignee: Merck Canada Inc.Inventors: Elise Isabel, Christopher Mellon, Christian Beaulieu
-
Patent number: 8637706Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.Type: GrantFiled: January 31, 2012Date of Patent: January 28, 2014Assignee: Gtx, Inc.Inventors: James T. Dalton, Christina Barrett, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
-
Publication number: 20140018422Abstract: Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases.Type: ApplicationFiled: December 14, 2012Publication date: January 16, 2014Inventors: Jeffrey Karpen, Sarah Kirk, Adriana Andrade, Michelle Schaffer, Kenneth Melich
-
Patent number: 8629274Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.Type: GrantFiled: December 21, 2012Date of Patent: January 14, 2014Assignee: Novira Therapeutics, Inc.Inventors: George D. Hartman, Osvaldo A. Flores
-
Publication number: 20130338092Abstract: This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.Type: ApplicationFiled: August 16, 2013Publication date: December 19, 2013Inventors: Kimberly Hartwell, Malcolm A.S. Moore, David T. Scadden, Stuart L. Schreiber, Todd R. Golub, Benito Munoz, Benjamin L. Ebert, Andrew M. Stern, Peter G. Miller, D. Gary Gilliland, Anne Van Dyk Carpenter, David J. Logan, Joseph Negri, Nicola Tolliday, Alykhan Shamji, Siddhartha Mukherjee, Alison Stewart
-
Patent number: 8609732Abstract: The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.Type: GrantFiled: June 17, 2009Date of Patent: December 17, 2013Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, Institut Curie, Centre National de la Recherche ScientfiqueInventors: Daniel Gillet, Julien Barbier, Ludger Johannes, Bahne Stechmann, Siau-Kun Bai
-
Publication number: 20130331457Abstract: Methods of treating bladder cancer are disclosed. The methods include administering to a patient a therapeutically effective amount of a 4-iodo-3-nitrobenzamide or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 29, 2012Publication date: December 12, 2013Applicant: BIPAR SCIENCES, INC.Inventors: Ernest KUN, Jerome MENDELEYEV, Carol BASBAUM, Hassan LEMJABBAR-ALAOUI, Valeria S. OSSOVSKAYA
-
Patent number: 8598207Abstract: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.Type: GrantFiled: May 22, 2012Date of Patent: December 3, 2013Assignee: Adolor CorporationInventor: John D. Buehler
-
Patent number: 8592438Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.Type: GrantFiled: March 16, 2009Date of Patent: November 26, 2013Assignee: Sumitomo Chemical Intellectual Property Service, LtdInventors: Masanao Takaishi, Norio Kimura
-
Publication number: 20130303545Abstract: The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease.Type: ApplicationFiled: September 20, 2011Publication date: November 14, 2013Inventors: Tamara Maes, Carlos Buesa Arjol
-
Patent number: 8575391Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].Type: GrantFiled: April 1, 2010Date of Patent: November 5, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshiaki Isshiki, Yasunori Kohchi, Eisaku Mizuguchi, Hitoshi Iikura, Yasuaki Matsubara, Shinji Tsujii, Nobuo Shimma, Masanori Miwa, Satoshi Aida, Masami Kohchi, Takeshi Murata, Kosuke Aso
-
Publication number: 20130289076Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.Type: ApplicationFiled: October 7, 2011Publication date: October 31, 2013Inventors: Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe, Marc Murtinell Pedemonte, Alberto Ortega Muñoz, Núrla Valls Vidal
-
Publication number: 20130274267Abstract: The present invention relates to the use of potent selective LSD1 inhibitors and LSD1/MAO-B iithibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defmed herein, for treating or preventing viral infection and treating or preventing reacti - vation of a virus after latency.Type: ApplicationFiled: February 24, 2011Publication date: October 17, 2013Inventors: Julio Cesar Castro Palomino Laria, Alberto Ortega Munoz, Nathalie Guibourt, Jonathan Alleman Baker
-
Publication number: 20130261132Abstract: Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.Type: ApplicationFiled: November 21, 2011Publication date: October 3, 2013Applicant: LEO PHARMA A/SInventors: Per Vedso, Lars Kristian Albert BlÆher
-
Patent number: 8546451Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: GrantFiled: February 23, 2010Date of Patent: October 1, 2013Assignee: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
-
Publication number: 20130252945Abstract: An amorphous formulations of a pharmaceutical includes a composition of the formula [A]x[MpClq]y, the composition being an ionic liquid with a melting temperature below 150° C., wherein [MpClq] is a metal chloride, x is 1, 2, 3, or 4, p is 1, 2, 3, or 4, q is 1, 2, 3, 4, 5, 6, 7, 8, or 9, and y is 1 or 2, wherein each A is a cation that is a pharmaceutical or a cation precursor that is a pharmaceutical.Type: ApplicationFiled: March 25, 2013Publication date: September 26, 2013Inventors: Katherine Lovejoy, Rico Del Sesto, Andrew Koppisch
-
Publication number: 20130245084Abstract: Compounds of general formula (I) their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.Type: ApplicationFiled: November 21, 2011Publication date: September 19, 2013Applicant: LEO PHARMA A/SInventor: Kristoffer Mansson
-
Publication number: 20130231311Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.Type: ApplicationFiled: April 16, 2013Publication date: September 5, 2013Inventors: Stephen J. FARR, John TURANIN, Roger HAWLEY, Jeffrey A. SCHUSTER
-
Publication number: 20130230542Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.Type: ApplicationFiled: March 1, 2013Publication date: September 5, 2013Applicants: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATIInventors: Edward J. Merino, James C. Mulloy, Guorui Li, Tiffany Bell-Horwath
-
Publication number: 20130231393Abstract: A compound of formula (I): or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or hydrate thereof are described. Also described, is the use of such a compound, salt, solvate or hydrate in the preparation of a medicament intended to treat rosacea.Type: ApplicationFiled: June 29, 2011Publication date: September 5, 2013Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Jérôme Aubert
-
Publication number: 20130224312Abstract: This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer cells that are homologous recombination-deficient are likely to be susceptible or resistant to PARP inhibitors and platinating agents are provided.Type: ApplicationFiled: November 16, 2012Publication date: August 29, 2013Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventor: Mayo Foundation for Medical Education and Research
-
Publication number: 20130217660Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.Type: ApplicationFiled: May 12, 2011Publication date: August 22, 2013Inventors: Dong-Ming Shen, John S. Debenham, Thomas H. Graham, Matthew J. Clements, Yong Zhang
-
Publication number: 20130217775Abstract: Nasal formulations of metoclopramide are administered for the treatment of symptoms associated with female gastroparesis. Also provided are methods of treating symptoms of female gastroparesis with nasal metoclopramide.Type: ApplicationFiled: August 23, 2012Publication date: August 22, 2013Applicant: Evoke Pharma, Inc.Inventors: Matthew J. D'Onofrio, David A. Gonyer, Marilyn R. Carlson
-
Publication number: 20130213393Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.Type: ApplicationFiled: October 25, 2012Publication date: August 22, 2013Applicant: EVOKE PHARMA, INC.Inventor: Evoke Pharma, Inc.
-
Publication number: 20130210899Abstract: A methodology and pharmaceutical and gene therapies for the treatment and regulation of memory function are provided. The invention identifies specific HDAC, and in particular, HDAC3 and HDAC4 as negative regulators of memory formation and specifically targets one or both HDAC3 and HDAC4 for down-regulation. By specifically targeting HDAC3 and HDAC4 with small molecule inhibitors and gene therapies it is possible to provide a powerful therapeutic approach to facilitate gene expression during memory formation that can lead to the regulation and treatment of memory disorders.Type: ApplicationFiled: July 28, 2011Publication date: August 15, 2013Applicant: The Regents of the University of CaliforniaInventor: Marcelo Andres Wood
-
Publication number: 20130210779Abstract: The present invention provides means for identifying or classifying breast tumors based on the levels of nuclear cathepsin-L (CTSL) and nuclear p53 binding protein (53BP1), and methods of treating thereof.Type: ApplicationFiled: February 15, 2013Publication date: August 15, 2013Applicant: The Washington UniversityInventor: The Washington University
-
Publication number: 20130203738Abstract: The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g.Type: ApplicationFiled: February 9, 2011Publication date: August 8, 2013Applicants: NAGOYA CITY UNIVERSITY, NAGASAKI UNIVERSITYInventors: Yoshifumi Nishimura, Aritaka Nagadoi, Yuuka Hirao, Yoshio Goshima, Naoya Yamashita, Naoki Miyata, Takayoshi Suzuki, Ryuta Hiraishi, Hiroshi Ueda
-
Patent number: 8501814Abstract: A compound of formula (I), an isomer, metabolite, or a pharmaceutically acceptable salt or ester thereof is disclosed. Compounds of the invention possess utility as a tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of hypogonadism, muscle wasting, osteoporosis, benign prostate hyperplasia, obesity associated with a metabolic syndrome, male and female sexual dysfunction and reduced libido, and androgen decline in aging male or female.Type: GrantFiled: March 2, 2007Date of Patent: August 6, 2013Assignee: Orion CorporationInventors: Jari Ratilainen, Olli Törmäkangas, Arja Karjalainen, Paavo Huhtala
-
Patent number: 8497304Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: January 19, 2012Date of Patent: July 30, 2013Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita